Oculis (NASDAQ:OCS – Get Free Report) and Palisade Bio (NASDAQ:PALI – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, valuation, institutional ownership, dividends and profitability.
Analyst Recommendations
This is a breakdown of recent recommendations and price targets for Oculis and Palisade Bio, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Oculis | 1 | 0 | 9 | 0 | 2.80 |
| Palisade Bio | 1 | 0 | 8 | 2 | 3.00 |
Oculis presently has a consensus target price of $38.89, indicating a potential upside of 456.11%. Palisade Bio has a consensus target price of $9.29, indicating a potential upside of 718.12%. Given Palisade Bio’s stronger consensus rating and higher possible upside, analysts clearly believe Palisade Bio is more favorable than Oculis.
Valuation & Earnings
This table compares Oculis and Palisade Bio”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Oculis | $1.45 million | 279.62 | -$119.44 million | ($1.74) | -4.02 |
| Palisade Bio | $500,000.00 | 395.60 | -$16.78 million | ($0.48) | -2.36 |
Palisade Bio has lower revenue, but higher earnings than Oculis. Oculis is trading at a lower price-to-earnings ratio than Palisade Bio, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Oculis and Palisade Bio’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Oculis | -8,613.92% | -39.24% | -33.45% |
| Palisade Bio | N/A | -33.47% | -31.79% |
Institutional and Insider Ownership
22.3% of Oculis shares are owned by institutional investors. Comparatively, 11.8% of Palisade Bio shares are owned by institutional investors. 0.1% of Palisade Bio shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Volatility & Risk
Oculis has a beta of 0.67, indicating that its stock price is 33% less volatile than the S&P 500. Comparatively, Palisade Bio has a beta of 1.61, indicating that its stock price is 61% more volatile than the S&P 500.
Summary
Palisade Bio beats Oculis on 12 of the 15 factors compared between the two stocks.
About Oculis
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. The company is based in Zug, Switzerland.
About Palisade Bio
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor, currently under pre-clinical development as a therapeutic for patients living with inflammatory bowel diseases, including ulcerative colitis and Crohn's disease (CD), as well as develops PALI-1908, an oral, selective PDE4 inhibitor prodrug that is locally bioactivated in the terminal ileum of CD patients, currently in the research stage. It has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; a license agreement with the Regents of the University of California; a co-development and distribution agreement with Newsoara Biopharma Co., Ltd; and a transformative strategic collaboration with Strand Life Sciences for advancing precision medicine for ulcerative colitis therapy. The company is based in Carlsbad, California.
Receive News & Ratings for Oculis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oculis and related companies with MarketBeat.com's FREE daily email newsletter.
